Emergent BioSolutions Inc. (EBS) insider trading

By person

30 insiders · 209 transactions

3.3×

Joseph Papa holds only 3.3 times base salary in stock. $3.50M of shares against $1.04M in salary for 2025.

Salary from the company's own proxy. The shares are what Joseph Papa last reported holding, valued at $7.09, the price Common Stock was last bought or sold at on the open market here, on 7 Oct 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Fuad El-Hibri

Director

—

$62.78M (58)

−$62.78M

10,183,813

19.86%

$72.20M

+37.8%

Daniel Abdun-Nabi

CEO

—

$14.41M (13) scheduled

−$14.41M

144,553

0.2819%

$1.02M

−20.3%

Adam Havey

EVP, Business Operations

—

$10.53M (23) scheduled

−$10.53M

174,398

0.3401%

$1.24M

+323.3%

Robert Kramer

President and CEO

—

$10.12M (5) scheduled

−$10.12M

507,059

0.9889%

$3.60M

+619.3%

Ronald Richard

Director

—

$7.68M (19) scheduled

−$7.68M

123,761

0.2414%

$877.47K

+487.9%

Sue Bailey

Director

—

$4.45M (15)

−$4.45M

24,427

0.0476%

$173.19K

−31.8%

Louis W Sullivan

Director

—

$4.09M (4) scheduled

−$4.09M

139,098

0.2713%

$986.20K

+288.3%

Zsolt Harsanyi

Chairman

—

$2.74M (6)

−$2.74M

149,076

0.2907%

$1.06M

+316.2%

Kathryn C Zoon

Director

—

$2.19M (26)

−$2.19M

79,941

0.1559%

$566.78K

—

Jerome M Hauer

Director

—

$2.13M (7)

−$2.13M

57,508

0.1122%

$407.73K

+209.4%

George A Joulwan

Director

—

$2.04M (6)

−$2.04M

40,244

0.0785%

$285.33K

+82.0%

Sean Kirk

EVP, Manufacturing & Tech Ops

—

$965.64K (3) scheduled

−$965.64K

17,776

0.0347%

$126.03K

+45.9%

Donald W DeGolyer

Director

—

$784.40K (6)

−$784.40K

111,921

0.2183%

$793.52K

—

Joseph C Papa

President and CEO

$349.80K (1)

—

+$349.80K

493,153

0.9618%

$3.50M

—

Coleen Glessner

EVP, Quality & Ethics, and CPL

—

$306.08K (1)

−$306.08K

202,201

0.3944%

$1.43M

—

Neal Franklin Fowler

Director

—

$204.05K (1)

−$204.05K

160,847

0.3137%

$1.14M

—

Sujata Tyagi Dayal

Director

—

$201.13K (3) scheduled

−$201.13K

100,563

0.1961%

$712.99K

—

Keith Katkin

Director

—

$177.60K (2) scheduled

−$177.60K

96,294

0.1878%

$682.72K

—

Marvin L White

Director

—

$171.02K (1)

−$171.02K

113,839

0.2220%

$807.12K

—

Richard S Lindahl

EVP, Chief Financial Officer

$112.38K (1)

—

+$112.38K

374,083

0.7296%

$2.65M

—

Paul Anthony Williams

SVP, Products Business

—

$78.55K (3) scheduled

−$78.55K

156,098

0.3044%

$1.11M

+1,565%

Seamus Mulligan

Director

—

601,731

1.17%

$4.27M

+1.3%

Jennifer Lynne Fox

EVP, Ext Aff, GC, Corp Sec

—

186,382

0.3635%

$1.32M

+2,471%

William Hartzel

SVP, Bioservices

—

185,558

0.3619%

$1.32M

+416.6%

Simon C Lowry

SVP, R&D, CMO

—

177,914

0.3470%

$1.26M

—

Jessica Perl

SVP, General Counsel, Corp Sec

—

165,286

0.3224%

$1.17M

+2,329%

Atul Saran

EVP, Chief Strat & Dev Officer

—

86,645

0.1690%

$614.31K

—

Katherine Strei

EVP, Chief HR Officer

—

62,824

0.1225%

$445.42K

+532.0%

John D Fowler Jr

Director

—

30,350

0.0592%

$215.18K

—

Karen L. Smith

EVP, Chief Medical Officer

—

11,888

0.0232%

$84.29K

+88.4%

Emergent BioSolutions Inc.

What the insiders did Net selling

By person